Myoinositol vs. Metformin for Polycystic Ovarian Syndrome (PCOS): Impact on Metabolic Health and Fertility
Key facts
- Who runs it
- Benha University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 156 people enrolled
- Started
- 25 Nov 2024
- Ended
- 18 Jun 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Metformin Hydrochloride 500 MG
- Myoinositol
- Record updated
- 10 July 2025
Who can take part
- Age
- 23 years to 47 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients presenting manifestations suggestive of having PCOS
- Patients were free of exclusion criteria
Who cannot take part
- Patients who were on medical therapy of PCOS, antidiabetic or/and antihypertensive therapy
- Patients with dyslipidemia, hereditary lipoprotein disorders:
- Patients with chronic liver or kidney diseases
- Patients who were maintained on a diet regimen, or/and regular exercise
- Patients who underwent laparoscopic drilling
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study aimed to assess how a 6-month insulin sensitizer therapy impacts insulin resistance, glucose tolerance, and hormonal levels in women with PCOS. Researchers evaluated 156 PCOS patients, measuring their BMI, HOMA-IR (for insulin resistance), TyG index, TyG index-BMI, and total testosterone. Participants were divided into two groups, receiving either metformin or a myoinositol/d-chiro-inositol combination for six months, after which all parameters were re-evaluated to determine the percentage of change.
The 2 groups in the trial
- Myoinositol GroupExisting treatment, for comparison
Patients presenting manifestations suggestive of having PCOS were evaluated for enrollment in the study, and took the tablets containing myoinositol/d-chiro-inositol combination (MYO/DCI) in 40:1 ratio
Treatment: Myoinositol
- Metformin GroupExisting treatment, for comparison
Patients presenting manifestations suggestive of having PCOS were evaluated for enrollment in the study, and took metformin (MET) hydrochloride 500 mg
Treatment: Metformin Hydrochloride 500 MG
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Myoinositol Therapy May Adjust The Metabolic Deregulation in Infertile Polycystic Ovarian Syndrome (PCOS) Women Through Modulation of The TyG Index-BMI: A Comparative Study Versus Metformin
- Record updated
- 10 July 2025